Establishment Labs (ESTA) Set to Announce Quarterly Earnings on Thursday

Establishment Labs (NASDAQ:ESTA - Get Free Report) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Establishment Labs to post earnings of ($0.61) per share for the quarter. Establishment Labs has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company's earnings conference call can do so using this link.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The firm had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. Establishment Labs's revenue was down 9.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.65) earnings per share. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Establishment Labs Stock Down 4.2 %

Shares of Establishment Labs stock traded down $1.88 during trading on Thursday, reaching $43.09. The company's stock had a trading volume of 328,970 shares, compared to its average volume of 374,501. The company has a 50-day simple moving average of $43.21 and a two-hundred day simple moving average of $46.07. Establishment Labs has a 1-year low of $16.96 and a 1-year high of $60.12. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -14.46 and a beta of 1.20. The company has a quick ratio of 2.91, a current ratio of 4.44 and a debt-to-equity ratio of 4.30.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Stephens restated an "overweight" rating and set a $68.00 price objective on shares of Establishment Labs in a report on Wednesday, August 7th. Citigroup boosted their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. reduced their target price on Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a research note on Wednesday, August 7th. Finally, BTIG Research boosted their price target on Establishment Labs from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Monday, October 14th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $58.83.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.